N-[5-[[(3-Chlorophenyl)amino]sulfonyl]-2-hydroxyphenyl]-3,4-dihydro-3-methyl-4-oxo-1-phthalazineacetamide | 1016456-76-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-[5-[[(3-Chlorophenyl)amino]sulfonyl]-2-hydroxyphenyl]-3,4-dihydro-3-methyl-4-oxo-1-phthalazineacetamide
• 英文别名: N-[5-[(3-chlorophenyl)sulfamoyl]-2-hydroxyphenyl]-2-(3-methyl-4-oxophthalazin-1-yl)acetamide
• CAS: 1016456-76-0
• 化学式: C₂₃H₁₉ClN₄O₅S
• 分子量: 498.9
• InChiKey: CLWDCBBEVQRZLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  137
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Mouse Models Having a Knockin Scavenger Receptor Class B Type I
  申请人：Beth Israel Deaconess Medical Center, Inc

  公开号：US20190289835A1

  公开（公告）日：2019-09-26

  The present invention relates to animal models that expresses SR-BIΔCT knockin. The present invention further includes animal models that express SR-BIΔCT and also have reduced expression or activity of ApoE and/or LDLR, wherein the latter can be accomplished by use of a compound or genetic manipulation of the gene. The present invention relates to mouse models crossed with SR-BIΔCT knockin mice. Specifically, the present invention relates to SR-BIΔCT knockin mice crossed with apolipoprotein E (ApoE) knockout mice (SR-BIΔCT/apoE KO), a hypoE mouse (also referred to as ApoeR61 h/h which expresses an impaired ApoE protein (SR-BIΔCT/ApoeR61 h/h )), or a LDLR knockout mouse (SR-BIΔCT/LDLR KO). Screening methods and compounds using these mouse models are also encompassed.
• [EN] MOUSE MODELS HAVING A KNOCKIN SCAVENGER RECEPTOR CLASS B TYPE I<br/>[FR] MODÈLES DE SOURIS À RÉCEPTEUR ÉBOUEUR KNOCK-IN DU TYPE I CLASSE B
  申请人：BETH ISRAEL DEACONESS MEDICAL CT INC

  公开号：WO2018049162A2

  公开（公告）日：2018-03-15

  The present invention relates to animal models that expresses SR-BIΔCT knockin. The present invention further includes animal models that express SR-BIΔCT and also have reduced expression or activity of ApoE and/or LDLR, wherein the latter can be accomplished by use of a compound or genetic manipulation of the gene. The present invention relates to mouse models crossed with SR-BIΔCT knockin mice. Specifically, the present invention relates to SR-BIΔCT knockin mice crossed with apolipoprotein E (ApoE) knockout mice (SR-BIΔCT/apoE KO), a hypoE mouse (also referred to as ApoeR61h/h which expresses an impaired ApoE protein (SR-BIΔCT/ ApoeR61)), or a LDLR knockout mouse (SR-BIΔCT/LDLR KO). Screening methods and compounds using these mouse models are also encompassed.